## Abstract Peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ) is a member of the nuclear hormone receptor superfamily of ligand‐activated transcription factors and a crucial regulator of cellular differentiation. PPAR‐γ ligands have been demonstrated to inhibit growth of several cancer cell
✦ LIBER ✦
Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer
✍ Scribed by Keshamouni, Venkateshwar G; Reddy, Raju C; Arenberg, Douglas A; Joel, Binju; Thannickal, Victor J; Kalemkerian, Gregory P; Standiford, Theodore J
- Book ID
- 110067970
- Publisher
- Nature Publishing Group
- Year
- 2004
- Tongue
- English
- Weight
- 330 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0950-9232
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Activation of peroxisome proliferator-ac
✍
Mingyue Li; Tak W. Lee; Tony S.K. Mok; Timothy D. Warner; Anthony P.C. Yim; Geor
📂
Article
📅
2005
🏛
John Wiley and Sons
🌐
English
⚖ 589 KB
Inhibition of peroxisome proliferator-ac
✍
Atsushi Nakajima; Ayako Tomimoto; Koji Fujita; Michiko Sugiyama; Hirokazu Takaha
📂
Article
📅
2008
🏛
John Wiley and Sons
🌐
English
⚖ 611 KB
Peroxisome proliferator-activated recept
✍
Bren-Mattison, Yvette; Van Putten, Vicki; Chan, Daniel; Winn, Robert; Geraci, Ma
📂
Article
📅
2004
🏛
Nature Publishing Group
🌐
English
⚖ 383 KB
Peroxisome proliferator-activated recept
✍
Zhang Min; Zou Ping; Bai Ming; Jin Yang; Tao Xiaonan
📂
Article
📅
2003
🏛
Springer-Verlag
🌐
Chinese
⚖ 552 KB
Apoptosis induced by troglitazone is bot
✍
Mingyue Li; Tak W. Lee; Anthony P.C. Yim; Tony S.K. Mok; George G. Chen
📂
Article
📅
2006
🏛
John Wiley and Sons
🌐
English
⚖ 493 KB
👁 1 views
Primary culture model of peroxisome prol
✍
Yue Xu; Sunita Iyengar; Richard L. Roberts; Scott B. Shappell; Donna M. Peehl
📂
Article
📅
2003
🏛
John Wiley and Sons
🌐
English
⚖ 516 KB
## Abstract BRL 49653 (rosiglitazone) is a thiazolidinedione anti‐diabetic drug that activates the nuclear receptor, peroxisome proliferator‐activated receptor gamma (PPARγ). Pilot clinical trials have shown evidence of therapeutic activity of PPARγ agonists against prostate cancer. To more effecti